Advertisement
Advertisement
ASND
Ascendis Pharma A/S - ADR
226.01
USDSponsored
-3.00
-1.31%
Mar 13, 15:58 UTC -4
Closed
After-Market
226.11
+0.10
+0.04%
ASND Earnings Reports
Positive Surprise Ratio
ASND beat 16 of 41 last estimates.
39%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$287.10M
/$0.39
Implied change from Q4 25 (Revenue/ EPS)
+16.00%
/-170.91%
Implied change from Q1 25 (Revenue/ EPS)
+184.39%
/-124.68%
Ascendis Pharma A/S - ADR earnings per share and revenue
On Feb 11, 2026, ASND reported earnings of -0.55 USD per share (EPS) for Q4 25, missing the estimate of -0.04 USD, resulting in a -1098.26% surprise. Revenue reached 247.50 million, compared to an expected 251.23 million, with a -1.49% difference. The market reacted with a -1.53% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of 0.39 USD, with revenue projected to reach 287.10 million USD, implying an decrease of -170.91% EPS, and increase of 16.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Mineralys Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.40
Surprise
+26.40%
Corvus Pharmaceuticals, Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.15
Surprise
-13.72%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
+16.28%
ADC Therapeutics SA
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.04
Surprise
+85.39%
Kamada Ltd
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.07
Actual
$0.06
Surprise
-24.15%
Allogene Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.22
Actual
-$0.17
Surprise
+22.73%
Molecular Partners AG - ADR
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.32
Surprise
+7.09%
Whitehawk Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.15
Actual
-$0.34
Surprise
-116.42%
Codexis, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.04
Actual
$0.11
Surprise
+357.01%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
FAQ
What were Ascendis Pharma A/S - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Ascendis Pharma A/S - ADR reported EPS of -$0.55, missing estimates by -1098.26%, and revenue of $247.50M, -1.49% below expectations.
How did the market react to Ascendis Pharma A/S - ADR's Q4 2025 earnings?
The stock price moved down -1.53%, changed from $221.49 before the earnings release to $218.10 the day after.
When is Ascendis Pharma A/S - ADR expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Ascendis Pharma A/S - ADR's next earnings report?
Based on 12
analysts, Ascendis Pharma A/S - ADR is expected to report EPS of $0.39 and revenue of $287.10M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement